CompletedNCT00501293

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Researchers studied Methylphenidate Transdermal System, tracking side effects to assess long-term safety in young people with ADHD.

Medication studyAges 13–17United States

The study in practice

Understand this study

Researchers studied Methylphenidate Transdermal System, tracking side effects to assess long-term safety in young people with ADHD.

Listed age limits: 13 years to 17 years.

Listed locations: Scottsdale, United States · Lafayette, United States and 30 more locationsSee all locations and recruitment
Activities: Medication described in the protocol
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateAugust 2007

Recruitment status: Completed
Enrollment listed in the registry: 163
Sponsor: Noven Therapeutics
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 13 Years to 17 Years
Official registry ID: NCT00501293
Official title: Show the full official title
A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed

Scottsdale · Lafayette · Wildomar

29 more locations

FAQ

What did researchers investigate?

Researchers studied Methylphenidate Transdermal System, tracking side effects to assess long-term safety in young people with ADHD.

Who is behind this study?

The study sponsor is Noven Therapeutics.

Did this study involve medication?

Yes. The study involved medication, including Methylphenidate Transdermal System.

Who was this study for?

Listed age limits: 13 years to 17 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.